| Dr Robert M Laporte, MD | |
|
1105 Sixth St, Traverse City, MI 49684-2349 | |
| (303) 349-6839 | |
| Not Available |
| Full Name | Dr Robert M Laporte |
|---|---|
| Gender | Male |
| Speciality | Radiology - Radiation Oncology |
| Location | 1105 Sixth St, Traverse City, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255315891 | NPI | - | NPPES |
| 91093914 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 32504 (Colorado) | Primary |
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The invasion and spread of cancer cells to other parts of the body, known as metastasis, is a principal cause of death in patients diagnosed with breast cancer.
New research from the Massachusetts Eye and Ear, Harvard Medical School and Harvard Program in Speech and Hearing Bioscience and Technology may have discovered a key piece in the puzzle of how hearing works by identifying the role of the olivocochlear efferent system in protecting ears from hearing loss.
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
The European Union's Research Executive Agency has given the Technische Universitaet Muenchen (TUM) a green light to begin negotiations on a five-year co-funding grant. In a ranking of 70 proposals for COFUND support through the Marie Curie Program, a TUM proposal requesting 6.2 million euros to expand selected programs of the TUM Institute for Advanced Study was one of just 18 to win the top "A" rating.
› Verified 2 days ago
| Entity Name | Range Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669569265 PECOS PAC ID: 8022920024 Enrollment ID: O20031110000095 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The invasion and spread of cancer cells to other parts of the body, known as metastasis, is a principal cause of death in patients diagnosed with breast cancer.
New research from the Massachusetts Eye and Ear, Harvard Medical School and Harvard Program in Speech and Hearing Bioscience and Technology may have discovered a key piece in the puzzle of how hearing works by identifying the role of the olivocochlear efferent system in protecting ears from hearing loss.
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
The European Union's Research Executive Agency has given the Technische Universitaet Muenchen (TUM) a green light to begin negotiations on a five-year co-funding grant. In a ranking of 70 proposals for COFUND support through the Marie Curie Program, a TUM proposal requesting 6.2 million euros to expand selected programs of the TUM Institute for Advanced Study was one of just 18 to win the top "A" rating.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert M Laporte, MD 10550 S Monaco Way, Traverse City, MI 49684-6816 Ph: (303) 349-6839 | Dr Robert M Laporte, MD 1105 Sixth St, Traverse City, MI 49684-2349 Ph: (303) 349-6839 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The invasion and spread of cancer cells to other parts of the body, known as metastasis, is a principal cause of death in patients diagnosed with breast cancer.
New research from the Massachusetts Eye and Ear, Harvard Medical School and Harvard Program in Speech and Hearing Bioscience and Technology may have discovered a key piece in the puzzle of how hearing works by identifying the role of the olivocochlear efferent system in protecting ears from hearing loss.
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
The European Union's Research Executive Agency has given the Technische Universitaet Muenchen (TUM) a green light to begin negotiations on a five-year co-funding grant. In a ranking of 70 proposals for COFUND support through the Marie Curie Program, a TUM proposal requesting 6.2 million euros to expand selected programs of the TUM Institute for Advanced Study was one of just 18 to win the top "A" rating.
› Verified 2 days ago
Edward J Walsh, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1105 Sixth St, Traverse City, MI 49684 Phone: 231-935-0497 | |
Dr. Jesse Clark Johnson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1105 Sixth St, Traverse City, MI 49684 Phone: 231-935-0497 | |
Andrew Osetek, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1105 Sixth St, Traverse City, MI 49684 Phone: 231-935-5000 | |
Anthony Livorine, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1105 Sixth St, Traverse City, MI 49684 Phone: 231-935-0497 | |
Dr. Ryan Michael Holmes, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1105 Sixth St, Traverse City, MI 49684 Phone: 231-935-0497 | |
Dr. Daniel Pilade Dall'olmo, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 10850 E Traverse Hwy, Suite 60, Traverse City, MI 49684 Phone: 231-935-0497 | |
Dr. Charles Paul Williams, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1105 Sixth St, Traverse City, MI 49684 Phone: 231-935-0497 |